| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | lomeguatrib | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.8 |